Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|February 25, 2005
Pharmacogenomics and the drug discovery pipeline: when should it be implemented?Michelle A Penny, Duncan McHalePharmacogenomics|July 15, 2005
EPIDAUROS Biotechnologie AGHans-Peter Arnold, Peter Kluge, Simon MauchJournal of Orthopaedic Surgery and Research|May 11, 2023
Modic changes as seen on MRI are associated with nonspecific chronic lower back pain and disabilityLloyd G Czaplewski, Otis Rimmer, Duncan McHale, et al.Nature Reviews. Drug Discovery|January 31, 2015
Towards the taxonomy of human diseaseMartin Hofmann-Apitius, Marta E Alarcón-Riquelme, Chris Chamberlain, et al.Neuroscience Letters|October 12, 2007
Association between neprilysin polymorphisms and sporadic Alzheimer's diseaseLinda S Wood, Eve H Pickering, Duncan McHale, et al.Journal of Health Care for the Poor and Underserved|June 3, 2024
Health Insurance Coverage Predicts Health Care Use among Latine Immigrants in Two Policy ContextsTaryn Morrissey, Neko Michelle Castleberry, Duncan McHale, et al.Frontiers in Immunology|December 30, 2022
Impact of oral administration of single strain Lactococcus lactis spp. cremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteersMahdi Saghari, Pim Gal, Hendrika W Grievink, et al.Frontiers in Medicine|May 30, 2024
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasisBenjamin D Ehst, Bruce Strober, Andrew Blauvelt, et al.Research in Microbiology|June 12, 2003
Relationships between fuselloviruses infecting the extremely thermophilic archaeon Sulfolobus: SSV1 and SSV2Kenneth M Stedman, Qunxin She, Hien Phan, et al.Investigational New Drugs|August 20, 2025
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumorsJudy S Wang, Edward R Arrowsmith, J Thaddeus Beck, et al.Pageof 3